However, co-treatment of EIF5B and BAY 11-7082 (which antagonizes NF-κB activation) dismissed overexpression of EIF5B effect on HCC cells (Figs. 6F–6H). This evidence concerns the gene NFKB1 and hepatocellular carcinoma.